"Merck is investing heavily in its pipeline with p
Post# of 155592
(Total Views: 190)
Posted On: 08/03/2025 10:30:44 AM
Re: biloxiblues #155586
"Merck is investing heavily in its pipeline with promising compounds such as:
MK‑8527: a once-monthly oral PrEP candidate currently in Phase 2 trials .
Islatravir and MK‑8591A/B: other late-stage candidates aimed at prevention and treatment .
Merck and Gilead also formalized a co-development agreement in 2021 to jointly advance lenacapavir (Gilead) and islatravir (Merck) in long-acting HIV treatments”
Questions:
1. It reads like Merck is “investing heavily” internally and externally? Do we know how much of that includes us at this point? What is Merck’s “investment” with us?
2. Since Merck has a 4+ year history of working with Gilead on HIV, how long have they been working with us?
3. Are we part of the “other late-stage candidates” being combined with Islatravir?
MK‑8527: a once-monthly oral PrEP candidate currently in Phase 2 trials .
Islatravir and MK‑8591A/B: other late-stage candidates aimed at prevention and treatment .
Merck and Gilead also formalized a co-development agreement in 2021 to jointly advance lenacapavir (Gilead) and islatravir (Merck) in long-acting HIV treatments”
Questions:
1. It reads like Merck is “investing heavily” internally and externally? Do we know how much of that includes us at this point? What is Merck’s “investment” with us?
2. Since Merck has a 4+ year history of working with Gilead on HIV, how long have they been working with us?
3. Are we part of the “other late-stage candidates” being combined with Islatravir?
(0)
(0)